GlassScriptPhysician profile
Nikole Bobadilla
NPI 1790045110
$1,262.39
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $332 · 2021: $428 · 2024: $22.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $245.78 | 2019-2021 | |
| Abbvie INC. | $189.71 | 2019-2021 | |
| Therapeuticsmd, INC. | $153.44 | 2019-2021 | |
| Astellas Pharma US INC | $99.51 | 2019-2021 | |
| Avion Pharmaceuticals | $77.22 | 2019-2021 | |
| Mission Pharmacal Company | $54.03 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $50.80 | 2019-2021 | |
| Evofem Biosciences, INC. | $43.13 | 2021 | |
| Merck Sharp & Dohme LLC | $41.91 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.17 | 2020-2021 | |
| Agile Therapeutics, INC. | $35.67 | 2021 | |
| Hologic Sales and Service, LLC | $34.78 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $23.41 | 2019 | |
| Roche Diagnostics Corporation | $23.33 | 2019 | |
| Ascend Therapeutics US, LLC | $18.18 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $16.14 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.92 | 2019 | |
| Allergan, INC. | $12.20 | 2019 | |
| Duchesnay USA Incorporated | $11.51 | 2019 | |
| Sanofi Pasteur INC. | $11.34 | 2019 | |
| Novo Nordisk INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikole Bobadilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.